To the Editor In a systematic review and network meta-analysis, Sonbol and colleagues1 found that maintenance therapy was significantly associated with progression-free survival (PFS) but not overall survival (OS) compared with observation following first-line induction therapy for metastatic colorectal cancer. Additionally, all 3 maintenance strategies (fluoropyrimidine, bevacizumab, and fluoropyrimidine plus bevacizumab) significantly improved PFS but not OS compared with observation, whereas fluoropyrimidine and fluoropyrimidine plus bevacizumab ranked higher than bevacizumab in PFS and OS. However, we have some concerns regarding the methodological aspects of this work.